2. Academic Validation
  3. Platelet membrane-based bionic nanocarrier-targeted delivery of desferrioxamine mitigates secondary neurological damage in intracerebral hemorrhage

Platelet membrane-based bionic nanocarrier-targeted delivery of desferrioxamine mitigates secondary neurological damage in intracerebral hemorrhage

  • Biomater Adv. 2026 Mar:180:214595. doi: 10.1016/j.bioadv.2025.214595.
Yancheng Hong 1,  Yudie Cao 1,  Muhammad Abid Hayat 1,  Tianyi Sun 2,  Yu Si 1,  Tao Guo 1,  Fengmei Li 1,  Sijia He 1,  Zijuan Weng 1,  Hao Zuo 3,  Xin Sun 3,  Zheng Li 4,  Bo Chen 4,  Yong Wang 5,  Jiabo Hu 6
Affiliations

Affiliations

  • 1 Regenerative Medicine and Tissue Engineering Research Center, Institute of Medical Innovation and Translation, the Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China; Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, China; Institute of Cerebrovascular Disease, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, 212002, China.
  • 2 Department of Medical Imaging, School of Medicine, Jiangsu University, Zhenjiang, 212013, China.
  • 3 Zhenjiang Blood Center, Zhenjiang, 212000, China.
  • 4 Institute of Cerebrovascular Disease, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, 212002, China.
  • 5 Regenerative Medicine and Tissue Engineering Research Center, Institute of Medical Innovation and Translation, the Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China.
  • 6 Regenerative Medicine and Tissue Engineering Research Center, Institute of Medical Innovation and Translation, the Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China; Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, Department of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, China; Institute of Cerebrovascular Disease, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, 212002, China; Zhenjiang Blood Center, Zhenjiang, 212000, China. Electronic address: [email protected].
PMID: 41223662 DOI: 10.1016/j.bioadv.2025.214595
Abstract

Intracerebral hemorrhage (ICH) is a severe subtype of acute stroke with high mortality and disability rates, primarily due to its complex pathology, emphasizing the need for therapeutic strategies. There are an increasing number of in-depth studies on ICH showing ICH continues to be a significant threat to individuals. Desferrioxamine mesylate (DFO) has shown neuroprotective effects, but its short half-life, lack of immune evasion, dosage toxicity, and poor targeting to hemorrhagic sites limit its therapeutic efficacy. To overcome these challenges, this study designed a platelet membrane (PM)-encapsulated bionic nanocarrier (PM-DFO) for the targeted delivery of DFO for the treatment of secondary brain injury following ICH. The PM-DFO utilizes platelet membrane proteins to facilitate the translocation of the drug at the targeted intracerebral hemorrhage-site, and provide an immune-evading drug, which can prolong the circulation time of the drug in vivo. In vitro studies showed that the PM-DFO chelated free iron, and inhibited Reactive Oxygen Species (ROS) formation from Fenton reactions, while attenuating heme's neurotoxicity on N2a cells. In vivo studies showed that the PM-DFO localized to the ICH site, reduced the size of the hematoma, iron deposition, and edema, improved neurological function, and reduced the neuroinflammatory response. Overall, this study introduces a novel approach for the treatment of ICH by improving the targeted delivery and prolonged release of the drug, along with reducing neuroinflammation and neuroprotection, providing new avenues for future clinical research to treat ICH.

Keywords

Fenton reaction; Intracerebral hemorrhage; Iron overload; Platelet membrane; Secondary brain injury.

Figures
Products